PBYI Q1 2023 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+15.4% YoY

Gross Profit

$40M75.0% margin

Operating Income

$4M8.3% margin

Net Income

$1M2.7% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

-19.6%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$196M

Total Liabilities

$170M

Stockholders' Equity

$26M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$46M	+15.4%
Gross Profit	$40M	$35M	+13.4%
Operating Income	$4M	-$747,000	+684.3%
Net Income	$1M	-$3M	+141.2%

Revenue Segments

Product

$47M89%

Royalty

$6M11%